PVLA Stock — Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc. (PVLA)

Updated October 16, 2026.

PVLA is a Stock. Total return is -45.3% over the past 11.8 years, 396.2 points behind SPY at 350.9%.

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing topical therapies for rare genetic skin diseases, with its lead candidate QTORIN rapamycin in Phase 3 trials for microcystic lymphatic malformations and Phase 2 trials for cutaneous venous malformations. The company does not currently distribute to shareholders. This security appeals to investors with high risk tolerance who are willing to hold shares in an early-stage drug developer with no established revenue, as returns depend entirely on the success of its clinical trials and potential future commercialization.

PVLA performance versus SPY

Price and return data through 2026-10-16.

Total return is -45.3% over the past 11.8 years, 396.2 points behind SPY at 350.9%. Over the past year its total return — price change plus distributions reinvested — is 64.5%. Its deepest 1-year drawdown was 31.1%.

PVLA key facts

Asset type

Stock

Asset class

Equity

Inception date

01/02/2015

Distribution frequency

None

Last close

$120.30 (as of 2026-10-16)

Market cap

$1,733,331,362

Average volume

179489.0

Payout ratio

0.0%

EPS

$-4.85

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PVLA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 31.1%.

Who may consider PVLA — and who may not

It is a weaker fit for investors who need monthly cash flow (PVLA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on PVLA

• All tickers starting with P

Tagged: Healthcare.

Frequently asked questions